RecruitingSkin CancerKidney Transplant Recipients
Pilot Trial of Supplemental Vitamin A and Nicotinamide
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.
Sponsor: Rhode Island Hospital
You may qualify if…
- ✓ 18 years old or greater;
- ✓ Either History of 2 or more histologically confirmed invasive cutaneous SCCs in the past 2 years or
- ✓ At least one previously billed Healthcare Common Procedure Coding System code 17004 (destruction of 15 or more benign or premalignant lesions of the integumentary system);
- ✓ Understands, reads, and writes English proficiently.
You may not qualify if…
- ✕ Liver disease;
- ✕ Active peptic ulcer disease;
- ✕ Recent myocardial infarction;
- ✕ Hypotension;
- ✕ Internal malignancy within past 5 years;
- ✕ Renal impairment with eGFR\<15 mL/min/1.73 m2;
- ✕ Being unable for follow up due to social reasons;
- ✕ Gorlin's syndrome or other genetic skin cancer syndrome;
Where it's recruiting
Rhode Island
Providence
Source: ClinicalTrials.gov · NCT05702398 · last updated 2026-03-20